Literature DB >> 11174852

Transcriptional activation of heat shock protein 27 gene expression by 17beta-estradiol and modulation by antiestrogens and aryl hydrocarbon receptor agonists.

W Porter1, F Wang, R Duan, C Qin, E Castro-Rivera, K Kim, S Safe.   

Abstract

Heat shock protein 27 (Hsp 27) is expressed in mammary tumors and may play a role in tumor growth and response to anti-neoplastic drug therapy. 17beta-Estradiol (E2) induces Hsp 27 mRNA levels in MCF-7 human breast cancer cells, and we have investigated the comparative inhibitory mechanisms using the aryl hydrocarbon receptor (AhR) agonist, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and the direct-acting antiestrogen ICI 164,384. TCDD inhibited E2-induced Hsp 27 gene expression and analysis of the Hsp 27 gene promoter showed that the inhibitory response was associated with AhR interactions with a pentanucleotide motif at -3 to +2 in the promoter that corresponded to the core sequence of a dioxin responsive element. In contrast, ICI 164,384 induced Hsp 27 gene expression and reporter gene activity in MCF-7 cells and this represents one of the few examples of the estrogen receptor-alpha (ERalpha) agonist activity of the 'pure' antiestrogen ICI 164,384.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11174852     DOI: 10.1677/jme.0.0260031

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  13 in total

1.  Aryl hydrocarbon receptor modulation of estrogen receptor α-mediated gene regulation by a multimeric chromatin complex involving the two receptors and the coregulator RIP140.

Authors:  Zeynep Madak-Erdogan; Benita S Katzenellenbogen
Journal:  Toxicol Sci       Date:  2011-11-09       Impact factor: 4.849

Review 2.  Regulation of constitutive and inducible AHR signaling: complex interactions involving the AHR repressor.

Authors:  Mark E Hahn; Lenka L Allan; David H Sherr
Journal:  Biochem Pharmacol       Date:  2008-09-20       Impact factor: 5.858

Review 3.  Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action.

Authors:  Erin K Shanle; Wei Xu
Journal:  Chem Res Toxicol       Date:  2010-11-05       Impact factor: 3.739

4.  Ah Receptor Pathway Intricacies; Signaling Through Diverse Protein Partners and DNA-Motifs.

Authors:  D P Jackson; A D Joshi; C J Elferink
Journal:  Toxicol Res (Camb)       Date:  2015-03-17       Impact factor: 3.524

5.  The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes.

Authors:  Mark Wormke; Matthew Stoner; Bradley Saville; Kelcey Walker; Maen Abdelrahim; Robert Burghardt; Stephen Safe
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

Review 6.  Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target.

Authors:  Stephen Safe; Syng-Ook Lee; Un-Ho Jin
Journal:  Toxicol Sci       Date:  2013-06-14       Impact factor: 4.849

7.  Cobaltous chloride and hypoxia inhibit aryl hydrocarbon receptor-mediated responses in breast cancer cells.

Authors:  Shaheen Khan; Shengxi Liu; Matthew Stoner; Stephen Safe
Journal:  Toxicol Appl Pharmacol       Date:  2007-05-25       Impact factor: 4.219

8.  The basic helix-loop-helix-PAS protein ARNT functions as a potent coactivator of estrogen receptor-dependent transcription.

Authors:  Sara Brunnberg; Katarina Pettersson; Elin Rydin; Jason Matthews; Annika Hanberg; Ingemar Pongratz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-16       Impact factor: 11.205

Review 9.  The aryl hydrocarbon receptor complex and the control of gene expression.

Authors:  Timothy V Beischlag; J Luis Morales; Brett D Hollingshead; Gary H Perdew
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2008       Impact factor: 1.807

10.  Growth of a human mammary tumor cell line is blocked by galangin, a naturally occurring bioflavonoid, and is accompanied by down-regulation of cyclins D3, E, and A.

Authors:  Tessa J Murray; Xinhai Yang; David H Sherr
Journal:  Breast Cancer Res       Date:  2006-03-27       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.